Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARNASA: Astegolimab in COPD
jRCT2031230619Phase 3Recruiting
- Sponsor
- Roche
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of astegolimab in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Roche. Primary endpoint: Annualized rate of moderate and severe COPD exacerbations. Started Feb 2024; status: recruiting.
02
Drugs
astegolimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2031230619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230619.